Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Johnson & Johnson

NYSE

Market Cap.

372.17B

Avg. Volume

7.46M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Johnson & Johnson!

Still processing it, give me a bit more time...

Johnson & Johnson News

Johnson & Johnson Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
jnj.com

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson Earnings & Revenue

Johnson & Johnson Financials

Table Compare

Compare JNJ metrics with:

   

Earnings & Growth

JNJ

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

JNJ

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

JNJ

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

JNJ

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Johnson & Johnson Income

Johnson & Johnson Balance Sheet

Johnson & Johnson Cash Flow

Johnson & Johnson Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioBuy
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Johnson & Johnson Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

4.81

Payment DateDividendFrequency
2024-06-041.24Quarterly
2024-03-051.19Quarterly
2023-12-051.19Quarterly
2023-09-071.19Quarterly
2023-06-061.19Quarterly

Historical Market Cap

Shares Outstanding

Johnson & Johnson Executives

NameRole
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine, R&D
Mr. Joaquin DuatoChief Executive Officer & Chairman
Mr. Joseph J. Wolk C.P.A.Executive Vice President & Chief Financial Officer
Ms. Jennifer L. TaubertExecutive Vice President & Worldwide Chairman of Innovative Medicine
Dr. Peter M. Fasolo Ph.D.Executive Vice President & Chief Human Resources Officer
NameRoleGenderDate of BirthPay
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine, R&D19588.57M
Mr. Joaquin DuatoChief Executive Officer & ChairmanMale19636.21M
Mr. Joseph J. Wolk C.P.A.Executive Vice President & Chief Financial OfficerMale19673.17M
Ms. Jennifer L. TaubertExecutive Vice President & Worldwide Chairman of Innovative MedicineFemale19643.1M
Dr. Peter M. Fasolo Ph.D.Executive Vice President & Chief Human Resources Officer19632.15M

Johnson & Johnson Insider Trades

Date1 May
NameREED JOHN C
RoleEVP, Innovative Medicine, R&D
TransactionAcquired
TypeM-Exempt
Shares22255
Date1 May
NameREED JOHN C
RoleEVP, Innovative Medicine, R&D
TransactionDisposed
TypeF-InKind
Shares10984
Date1 May
NameREED JOHN C
RoleEVP, Innovative Medicine, R&D
TransactionDisposed
TypeM-Exempt
Shares22255
Date25 Apr
NameBeckerle Mary C
RoleDirector
TransactionAcquired
TypeA-Award
Shares1385.697
Date25 Apr
NameHEWSON MARILLYN A
RoleDirector
TransactionAcquired
TypeA-Award
Shares1385.697
DateNameRoleTransactionTypeShares
1 MayREED JOHN CEVP, Innovative Medicine, R&DAcquiredM-Exempt22255
1 MayREED JOHN CEVP, Innovative Medicine, R&DDisposedF-InKind10984
1 MayREED JOHN CEVP, Innovative Medicine, R&DDisposedM-Exempt22255
25 AprBeckerle Mary CDirectorAcquiredA-Award1385.697
25 AprHEWSON MARILLYN ADirectorAcquiredA-Award1385.697

Discover More

Streamlined Academy

Johnson & Johnson

NYSE

Market Cap.

372.17B

Avg. Volume

7.46M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Johnson & Johnson News

Johnson & Johnson Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Johnson & Johnson Earnings & Revenue

Johnson & Johnson Income

Johnson & Johnson Balance Sheet

Johnson & Johnson Cash Flow

Johnson & Johnson Financials Over Time

Johnson & Johnson Executives

NameRole
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine, R&D
Mr. Joaquin DuatoChief Executive Officer & Chairman
Mr. Joseph J. Wolk C.P.A.Executive Vice President & Chief Financial Officer
Ms. Jennifer L. TaubertExecutive Vice President & Worldwide Chairman of Innovative Medicine
Dr. Peter M. Fasolo Ph.D.Executive Vice President & Chief Human Resources Officer
NameRoleGenderDate of BirthPay
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine, R&D19588.57M
Mr. Joaquin DuatoChief Executive Officer & ChairmanMale19636.21M
Mr. Joseph J. Wolk C.P.A.Executive Vice President & Chief Financial OfficerMale19673.17M
Ms. Jennifer L. TaubertExecutive Vice President & Worldwide Chairman of Innovative MedicineFemale19643.1M
Dr. Peter M. Fasolo Ph.D.Executive Vice President & Chief Human Resources Officer19632.15M

Johnson & Johnson Insider Trades

Date1 May
NameREED JOHN C
RoleEVP, Innovative Medicine, R&D
TransactionAcquired
TypeM-Exempt
Shares22255
Date1 May
NameREED JOHN C
RoleEVP, Innovative Medicine, R&D
TransactionDisposed
TypeF-InKind
Shares10984
Date1 May
NameREED JOHN C
RoleEVP, Innovative Medicine, R&D
TransactionDisposed
TypeM-Exempt
Shares22255
Date25 Apr
NameBeckerle Mary C
RoleDirector
TransactionAcquired
TypeA-Award
Shares1385.697
Date25 Apr
NameHEWSON MARILLYN A
RoleDirector
TransactionAcquired
TypeA-Award
Shares1385.697
DateNameRoleTransactionTypeShares
1 MayREED JOHN CEVP, Innovative Medicine, R&DAcquiredM-Exempt22255
1 MayREED JOHN CEVP, Innovative Medicine, R&DDisposedF-InKind10984
1 MayREED JOHN CEVP, Innovative Medicine, R&DDisposedM-Exempt22255
25 AprBeckerle Mary CDirectorAcquiredA-Award1385.697
25 AprHEWSON MARILLYN ADirectorAcquiredA-Award1385.697

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
jnj.com

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Johnson & Johnson!

Still processing it, give me a bit more time...

Johnson & Johnson Financials

Table Compare

Compare JNJ metrics with:

   

Earnings & Growth

JNJ

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

JNJ

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

JNJ

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

JNJ

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Johnson & Johnson Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

4.81

Payment DateDividendFrequency
2024-06-041.24Quarterly
2024-03-051.19Quarterly
2023-12-051.19Quarterly
2023-09-071.19Quarterly
2023-06-061.19Quarterly

Johnson & Johnson Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioBuy
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More